Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978569597> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2978569597 endingPage "v618" @default.
- W2978569597 startingPage "v618" @default.
- W2978569597 abstract "Abstract Background Among lung cancers, non- small cell lung cancer (NSCLC) accounts for approximately 80% of cases. It is one of the leading causes of cancer related mortality in US. Atezolizumab is a humanized monoclonal antibody against the programmed cell death-ligand 1 (PD-L1) protein. We have conducted a meta-analysis to evaluate the risk of first-line atezolizumab chemoimmunotherapy- associated immune-related adverse events (IRAEs) in patients with advanced NSCLC. Methods PUBMED, MEDLINE, EMBASE databases and meeting abstracts from inception through March 2019 were queried. Phase III RCTs that mention IRAEs as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Random effects model was applied. Results A total of 2725 patients with advanced NSCLC from four phase III RCTs were eligible. The study arm used standard chemotherapy regimens in combination with atezolizumab while control arm utilized only standard chemotherapy regimens. The RR of all-grade side effects were as follows: rash, 1.68 (95% CI: 1.13 – 2.50, p = 0.01); hepatitis, 2.57 (95% CI: 1.21– 5.49; p = 0.01); hypothyroidism, 6.27 (95% CI: 2.55 – 15.44, p Conclusions Our meta-analysis showed that the addition of atezolizumab to standard chemotherapy, contributed to higher incidence of all grades of rash, hepatitis and colitis with RR of 4.35 for grade 3 and 4 hepatitis. They also increased the risk of all-grade hypothyroidism, hyperthyroidism and pneumonitis. Timely intervention with proper supportive care will enhance patients’ quality of life, ultimately affecting patients’ compliance. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest." @default.
- W2978569597 created "2019-10-10" @default.
- W2978569597 creator A5007947157 @default.
- W2978569597 creator A5009931242 @default.
- W2978569597 creator A5012647187 @default.
- W2978569597 creator A5021125585 @default.
- W2978569597 creator A5026291608 @default.
- W2978569597 creator A5038585259 @default.
- W2978569597 creator A5046228031 @default.
- W2978569597 creator A5052566782 @default.
- W2978569597 creator A5060455526 @default.
- W2978569597 creator A5066300266 @default.
- W2978569597 creator A5070440946 @default.
- W2978569597 creator A5081584773 @default.
- W2978569597 creator A5084438015 @default.
- W2978569597 creator A5089431919 @default.
- W2978569597 creator A5089487423 @default.
- W2978569597 date "2019-10-01" @default.
- W2978569597 modified "2023-09-23" @default.
- W2978569597 title "Upfront atezolizumab chemoimmunotherapy-associated immune-related adverse events in patients with advanced non-small cell lung cancer" @default.
- W2978569597 doi "https://doi.org/10.1093/annonc/mdz260.028" @default.
- W2978569597 hasPublicationYear "2019" @default.
- W2978569597 type Work @default.
- W2978569597 sameAs 2978569597 @default.
- W2978569597 citedByCount "0" @default.
- W2978569597 crossrefType "journal-article" @default.
- W2978569597 hasAuthorship W2978569597A5007947157 @default.
- W2978569597 hasAuthorship W2978569597A5009931242 @default.
- W2978569597 hasAuthorship W2978569597A5012647187 @default.
- W2978569597 hasAuthorship W2978569597A5021125585 @default.
- W2978569597 hasAuthorship W2978569597A5026291608 @default.
- W2978569597 hasAuthorship W2978569597A5038585259 @default.
- W2978569597 hasAuthorship W2978569597A5046228031 @default.
- W2978569597 hasAuthorship W2978569597A5052566782 @default.
- W2978569597 hasAuthorship W2978569597A5060455526 @default.
- W2978569597 hasAuthorship W2978569597A5066300266 @default.
- W2978569597 hasAuthorship W2978569597A5070440946 @default.
- W2978569597 hasAuthorship W2978569597A5081584773 @default.
- W2978569597 hasAuthorship W2978569597A5084438015 @default.
- W2978569597 hasAuthorship W2978569597A5089431919 @default.
- W2978569597 hasAuthorship W2978569597A5089487423 @default.
- W2978569597 hasBestOaLocation W29785695971 @default.
- W2978569597 hasConcept C121608353 @default.
- W2978569597 hasConcept C126322002 @default.
- W2978569597 hasConcept C143998085 @default.
- W2978569597 hasConcept C197934379 @default.
- W2978569597 hasConcept C2775949291 @default.
- W2978569597 hasConcept C2776256026 @default.
- W2978569597 hasConcept C2777701055 @default.
- W2978569597 hasConcept C2780030458 @default.
- W2978569597 hasConcept C2780790343 @default.
- W2978569597 hasConcept C71924100 @default.
- W2978569597 hasConceptScore W2978569597C121608353 @default.
- W2978569597 hasConceptScore W2978569597C126322002 @default.
- W2978569597 hasConceptScore W2978569597C143998085 @default.
- W2978569597 hasConceptScore W2978569597C197934379 @default.
- W2978569597 hasConceptScore W2978569597C2775949291 @default.
- W2978569597 hasConceptScore W2978569597C2776256026 @default.
- W2978569597 hasConceptScore W2978569597C2777701055 @default.
- W2978569597 hasConceptScore W2978569597C2780030458 @default.
- W2978569597 hasConceptScore W2978569597C2780790343 @default.
- W2978569597 hasConceptScore W2978569597C71924100 @default.
- W2978569597 hasLocation W29785695971 @default.
- W2978569597 hasOpenAccess W2978569597 @default.
- W2978569597 hasPrimaryLocation W29785695971 @default.
- W2978569597 hasRelatedWork W2032912323 @default.
- W2978569597 hasRelatedWork W2390152934 @default.
- W2978569597 hasRelatedWork W2973398949 @default.
- W2978569597 hasRelatedWork W2978569597 @default.
- W2978569597 hasRelatedWork W2981870116 @default.
- W2978569597 hasRelatedWork W2988890314 @default.
- W2978569597 hasRelatedWork W3119456178 @default.
- W2978569597 hasRelatedWork W3158758782 @default.
- W2978569597 hasRelatedWork W4323921009 @default.
- W2978569597 hasRelatedWork W4366235027 @default.
- W2978569597 hasVolume "30" @default.
- W2978569597 isParatext "false" @default.
- W2978569597 isRetracted "false" @default.
- W2978569597 magId "2978569597" @default.
- W2978569597 workType "article" @default.